April 07, 2015 (Shareholders Foundation) - An investigation on behalf of investors, who currently hold shares of Catamaran Corp (USA) (NASDAQ:CTRX), was announced concerning whether the takeover of Catamaran Corp by OptumRx is unfair to NASDAQ:CTRX stockholders.

The investigation by a law firm concerns whether certain officers and directors of Catamaran Corp breached their fiduciary duties owed to NASDAQ:CTRX investors in connection with the proposed acquisition.

On March 30, 2015 OptumRx and Catamaran Corporation [NASDAQ: CTRX, TSX: CCT] announced they have agreed to combine. The agreement calls for the acquisition of Catamaran Corp (USA) (NASDAQ:CTRX) outstanding common stock for $61.50 per share in cash.

However, given that at least one analyst has set the high target price for NASDAQ:CTRX shares at $66.00 per share, the investigation concerns whether the offer is unfair to NASDAQ:CTRX stockholders. More specifically, the investigation concerns whether the Catamaran Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.

Catamaran Corp reported that its annual Total Revenue rose from over $4.97 billion in 2011 to over $21.58 billion in 2014 and that its respective Net Income increased from $91.79 million to $317.29 million.